Results of Combi-TED presented by OSE Immunotherapeutics

OSE Immunotherapeutics presented the results of its Phase 2 Combi-TED study at the ESMO Congress 2026 in Madrid. This study is evaluating the efficacy of Tedopi® in combination with an anti-PD1 agent or chemotherapy in patients with non-small cell lung cancer. Dr. Federico Cappuzzo led the research. The biotechnology company, which focuses on advancements in immuno-oncology and immuno-inflammation, has concentrated on Tedopi® as a second-line treatment. This multicenter study, including 105 patients in France, Italy, and Spain, primarily analyzes the one-year survival rate of treated individuals. The results were discussed during an oral presentation on October 25.